Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

13.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nailfold capillaroscopy and organ involvement in systemic sclerosis: a systematic review.

Best practice & research. Clinical rheumatology·2026
Same author

Capillaroscopy in the daily clinic of the pediatric rheumatologist.

Best practice & research. Clinical rheumatology·2024
Same author

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

An engineered glove to follow finger function in rheumatoid arthritis: an observational prospective study.

Rheumatology international·2023
Same author

Emerging nailfold capillaroscopic patterns in COVID-19: from acute patients to survivors.

Reumatismo·2023
Same author

Nailfold capillaroscopy in the rheumatological current clinical practice in Italy: results of a national survey.

Reumatismo·2022

Related Experiment Video

Updated: Mar 22, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.0K

Systemic sclerosis: markers and targeted treatments.

M Cutolo, A Sulli, C Pizzorni

    Acta Reumatologica Portuguesa
    |April 27, 2016
    PubMed
    Summary

    Systemic sclerosis (SSc) involves autoantibodies, microvasculopathy, and fibrosis. Future treatments may emerge from epigenetic studies, focusing on early intervention for vascular and autoimmune issues.

    Area of Science:

    • Immunology and Rheumatology
    • Vascular Biology
    • Fibrosis Research

    Background:

    • Systemic sclerosis (SSc) is an autoimmune disease characterized by autoantibody production, microvasculopathy, and excessive extracellular matrix (ECM) deposition.
    • Key clinical features include Raynaud's phenomenon (RP) and skin involvement, with potential for internal organ damage.
    • Current treatments address symptoms and organ-specific issues, but effective disease-modifying markers and targets remain under investigation.

    Purpose of the Study:

    • To review current and emerging therapeutic strategies for Systemic Sclerosis (SSc).
    • To highlight the importance of targeting early disease hallmarks: microvascular damage and autoimmune responses.
    • To explore the potential of epigenetic studies, particularly microRNAs, for future SSc diagnostics and therapeutics.

    More Related Videos

    Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
    09:08

    Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

    Published on: October 14, 2021

    6.4K
    Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
    08:09

    Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

    Published on: March 24, 2017

    8.7K

    Related Experiment Videos

    Last Updated: Mar 22, 2026

    Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
    04:44

    Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

    Published on: June 16, 2020

    21.0K
    Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
    09:08

    Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

    Published on: October 14, 2021

    6.4K
    Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
    08:09

    Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

    Published on: March 24, 2017

    8.7K

    Main Methods:

    • Review of existing literature on SSc pathophysiology and treatment modalities.
    • Analysis of therapies targeting vascular, immune, and fibrotic pathways.
    • Consideration of advanced treatments like hematopoietic stem cell transplantation (HSTC) and intravenous immunoglobulins (IVIG).

    Main Results:

    • Various therapies targeting vasculature (e.g., endothelin-1 receptor antagonists, PDE-5 inhibitors), immune system (e.g., DMARDs, biologics), and fibrosis are under evaluation.
    • Advanced treatments like HSTC and IVIG are options for refractory SSc.
    • Epigenetic research, specifically microRNAs, shows promise for novel diagnostic and therapeutic approaches.

    Conclusions:

    • Combination therapy is considered the optimal approach for SSc management.
    • Early intervention targeting microvascular dysfunction and autoimmune reactions is crucial for "at-risk" patients.
    • Future SSc management will likely integrate epigenetic insights and a multi-targeted therapeutic strategy.